Fundraising Fox
Alpheus Medical
Chanhassen, US · Founded 2020 · Delaware corporation · 12 employees on LinkedIn · 6 known investors
Find your way into Alpheus Medical
Sign up to see every warm intro you have to Alpheus Medical
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Alpheus Medical team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites. The company's lead program is in a randomized Phase 2b trial for newly diagnosed glioblastoma.
Founders & leadership
Board
Investors · 6
How we know: OrbiMed's portfolio page · the company's own site · board seat on SEC Form D · Not right? Tell us
How we know: the company's own site · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: SV Health Investors's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$82.7M disclosed across 7 rounds · 2017–2025
▶$60.5MraisedJul 2026 · 22 investors · BiotechnologyRule 506(b)
- Vijay AgarwalExecutive Officer, Director
- Jeremy LingExecutive Officer
- Imran EbaExecutive Officer
- John JohnsonDirector
- Robert SteinDirector
- Juan-Pablo MasDirector
- Peter ThompsonDirector
- Klaus VeitingerDirector
- Steve WeinerExecutive Officer
- Offering amount
- $67M
- Amount sold
- $60.5M
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$14MraisedNov 2022 · 4 investors · OtherRule 506(b)
- Peter ThompsonDirector
- Vijay AgarwalExecutive Officer, Director
- Terrance KurtenbachExecutive Officer
- Imran EbaDirector
- Klaus VeitingerDirector
- Aaron SandoskiDirector
- Offering amount
- $14M
- Amount sold
- $14M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedDec 2020 · 23 investors · Other Health CareRule 506(b)
- Vijay AgarwalExecutive Officer, Director
- William DavisExecutive Officer
- Imran EbaDirector
- Peter ThompsonDirector
- Aaron SandoskiDirector
- Klaus VeitingerDirector
- Offering amount
- $16M
- Amount sold
- $6M
- Sales commissions
- $301.9K
- Placement agents
- B. Riley Securities, Inc.
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$519KraisedMay 2020 · 12 investors · Other Health CareRule 506(b)
- Vijay AgarwalExecutive Officer, Director
- William DavisExecutive Officer
- Offering amount
- $700K
- Amount sold
- $519K
- First sale
- Oct 2019
- Incorporated
- Corporation, North Carolina
- Federal exemptions
- 06b
▶$1.3MraisedOct 2018 · 22 investors · Other Health CareRule 506(b)
- William DavisExecutive Officer
- Vijay AgarwalExecutive Officer, Director
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- First sale
- Apr 2018
- Incorporated
- Corporation, North Carolina, 2014
- Federal exemptions
- 06b
▶$150KraisedMar 2018 · 2 investors · Other Health CareRule 506(b)
- William DavisExecutive Officer, Director
- Vijay AgarwalExecutive Officer, Director
- Offering amount
- $150K
- Amount sold
- $150K
- First sale
- Jan 2018
- Incorporated
- Corporation, North Carolina, 2014
- Federal exemptions
- 06b
▶$225KraisedSep 2017 · 2 investors · Other Health CareRule 506(b)
- Vijay AgarwalExecutive Officer, Director
- Patrick GoraExecutive Officer
- Offering amount
- $300K
- Amount sold
- $225K
- First sale
- May 2017
- Incorporated
- Corporation, North Carolina, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Alpheus Medical.
In the news
Frequently asked questions
- What does Alpheus Medical do?
- Alpheus is a clinical-stage biotechnology company developing Porphyrin Metabolite Activation (PoMA™), a drug-led oncology approach designed to treat glioblastoma using proprietary low-intensity ultrasound to activate tumor-localized porphyrin metabolites. The company's lead program is in a randomized Phase 2b trial for newly diagnosed glioblastoma.
- Who are Alpheus Medical's investors?
- Alpheus Medical's investors include OrbiMed, HealthQuest Capital, Samsara BioCapital, SV Health Investors, Action Potential Venture Capital Ltd., BrightEdge.
- How much funding has Alpheus Medical raised?
- Alpheus Medical has disclosed $82.7M raised across 7 rounds.
- Where is Alpheus Medical headquartered?
- Alpheus Medical is headquartered in Chanhassen, US.